Study of the antioxidant status in patients with secondary lymphedema of the lower extremities under conservative treatment

Abstract

Aim. To assess the antioxidant status in patients with secondary lymphedema of the lower extremities who undergo different types of conservative treatment.

Methods. The study included 90 patients with secondary lymphedema of the lower extremities and 30 healthy volunteers. Group 1 participants (n=30) received compression therapy and Vitamin E at a dose of 400 IU/day, group 2 participants (n=30) compression therapy and a micronized purified flavonoid fraction 1000 mg/day, group 3 (n=30) compression therapy alone. Group 4 (n=30) comprised healthy volunteers. The level of malondialdehyde, the activity of superoxide dismutase, glutathione peroxidase, catalase, and the level of non-protein thiols (SH-groups) were determined at inclusion in the study and then after 1 and 3 months.

Results. In patients with secondary lymphedema, the initial level of glutathione peroxidase was higher by 768.22%, catalase — by 420.5%, malondialdehyde — by 60%, and the level of SH-groups was lower by 65,71% compared with the group of volunteers. In the first group, there was a significant decrease of 36.1% in the level of superoxide dismutase and a significant increase of 89.9% in the level of glutathione peroxidase at the end of therapy when compared with the level after 1 month. In the second group, catalase level significantly increased — by 33.3%, superoxide dismutase by 17.6%, and glutathione peroxidase by 61.3% compared to baseline values. The biochemical indicators of the endothelium significantly increased when using a combination of micronized purified flavonoid fraction and elastic compression in comparison with elastic compression alone and a combination with Vitamin E. In the third group, there were no significant differences in the levels of biochemical indicators of endothelial function.

Conclusion. Increased formation of lipid peroxidation products along with a decrease in the activity of antioxidant systems was revealed in patients with lower extremity secondary lymphedema compared with healthy volunteers; the most effective therapy aimed at correcting endothelial cell dysfunction is the use of micronized purified flavonoid fraction and elastic compression.

Keywords

lymphedema / endothelial dysfunction / endothelium / oxidative stress / antioxidants / lipid oxidation / MPFF

References

[1] Aspelund A., Robciuc M.R., Karaman S., Makinen T., Alitalo K. Lymphatic system in cardiovascular medicine. Circ. Res. 2016; 118 (3): 515–530. DOI: 10.1161/CIRCRESAHA.115.306544.

[2] Weiler M.J., Cribb M.T., Nepiyushchikh Zh., Nelson T.S., Dixon J.B. A novel mouse tail lymphedema model for obser­ving lymphatic pump failure during lymphedema deve­lopment. Sci. Rep. 2019; 9 (1): 10405. DOI: 10.1038/s41598-019-46797-2.

[3] Kalinin R.E., Suchkov I.A., Maksaev D.A. Endothelial dysfunction in patients with secondary lymphedema and methods of its correction (literature review). Nauka molodyh (Eruditio Juvenium). 2019; 7 (2): 283–293. (In Russ.)

[4] Калинин Р.Е., Сучков И.А., Максаев Д.А. Эндотелиальная дисфункция у пациентов с вторичной лимфедемой и способы её коррекции (обзор литературы). Наука молодых (Eruditio Juvenium). 2019; 7 (2): 283–293.

[5] Mendez U., Stroup E.M., Lynch L.L., Waller A.B., Goldman J. A chronic and latent lymphatic insufficiency follows recovery from acute lymphedema in the rat foreleg. Am. J. Phy­siol. Heart Circ. Physiol. 2012; 303: 1107–1113. DOI: 10.1152/ajpheart.00522.2012.

[6] Shevchenko A.V., Prokofyev V.F., Konenkov V.I., Khapaev R.S., Nimaev V.V. Polymorphism of vascular endothelial growth factor gene (VEGF) and matrix metalloproteinase (ММР) genes in primary limb lymphedema. Medical Immunology (Russia). 2020; 22 (3): 497–506. (In Russ.) DOI: 10.15789/1563-0625-POV-1913.

[7] Шевченко А.В., Прокофьев В.Ф., Коненков В.И., Хапаев Р.С., Нимаев В.В. Полиморфизм генов фактора роста эндотелия сосудов (VEGF) и матриксных металлопротеиназ (ММР) при первичной лимфедеме конечностей. Мед. иммунол. 2020; 22 (3): 497–506. DOI: 10.15789/1563-0625-POV-1913.

[8] Petuhov V.A. Endothelial dysfunction: current state of the art (based on the materials of the scien­tific symposium). Khirurgiya. Prilozhenie k zhurnalu Consilium Medicum. 2008; (1): 3–11. (In Russ.)

[9] Петухов В.А. Эндотелиальная дисфункция: современное состояние вопроса (по материалам научного симпозиума). Хирургия. Приложение к журналу Consilium Medicum. 2008; (1): 3–11.

[10] Pereira De Godoy J.M., Amador Franco Brigidio P., Buzato E., Fátima Guerreiro De Godoy M. Intensive outpatient treatment of elephantiasis. Int. Angiol. 2012; 5: 494–498. PMID: 22990514.

[11] Vasina L.V., Petrishchev N.N., Vlasov T.D. Markers of endothelial dysfunction. Regional blood circulation and microcirculation. 2017; 16 (1): 4–15. (In Russ.) DOI: 10.24884/1682-6655-2017-16-1-4-15.

[12] Васина Л.В., Петрищев Н.Н., Власов Т.Д. Эндотелиальная дисфункция и её основные маркёры. Регионарное кровообращение и микроциркуляция. 2017; 16 (1): 4–15. DOI: 10.24884/1682-6655-2017-16-1-4-15.

[13] Rajendran P., Rengarajan T., Thangavel J., Nishigaki Y., Sakthisekaran D., Sethi G., Nishigakiet I. The vascular endothelium and human diseases. Int. J. Biol. Sci. 2013; 9 (10): 1057–1069. DOI: 10.7150/ijbs.7502.

[14] Siems W.G., Brenke R., Beier A., Grune T. Oxidative stress in chronic lymphoedema. Q. J. Med. 2002; 95: 803–809. DOI: 10.1093/qjmed/95.12.803.

[15] Yarovenko G.V., Myshentsev P.N. Comprehensive treatment of patients with lymphedema of the lower extremities. Journal of experimental and clinical surgery. 2019; 12 (4): 230–234. (In Russ.) DOI: 10.18499/2070-478X-2019-12-4-230-234.

[16] Яровенко Г.В., Мышенцев П.Н. Комплексное лечение больных лимфедемой нижних конечностей. Вестн. эксперим. и клин. хир. 2019; 12 (4): 230–234. DOI: 10.18499/2070-478X-2019-12-4-230-234.

[17] Joseph W.J., Aschen S., Ghanta S., Cuzzone D., Albano N., Gardenier J., Savetsky I., Torrisi J., Mehrara B.J. Ste­rile inflammation after lymph node transfer improves lymphatic function and regeneration. Plast. Reconstr. Surg. 2014; 134 (1): 60–68. DOI: 10.1097/PRS.0000000000000286.

[18] Kalinin R.E., Suchkov I.A., Pshennikov A.S., Mzhavanadze N.D. Possibilities of pharmacotherapy for chronic venous insufficiency with diosmin preparations from the position of the endothelial functio­nal state. Angiologiya i sosudistaya hirurgiya. 2015; 21 (3): 91–97. (In Russ.)

[19] Калинин Р.Е., Сучков И.А., Пшенников А.С., Мжаванадзе Н.Д. Возможности фармакотерапии хронической венозной недостаточности препаратами диосмина с позиции функционального состояния эндотелия. Ангиол. и сосудист. хир. 2015; 21 (3): 91–97.

[20] Sommerburg O., Grune T., Hampl H., Riedel E., van Kuijk F.J.M.G., Ehrich J.H.H., Siems W.G. Does long-term treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialyzed patients? Nephrol. Dialysis Transpl. 1998; 13: 2583–2587. DOI: 10.1093/ndt/13.10.2583.

[21] Ohkuma M. Lipiperoxide in the dermis of patients with lymph stasis. Lymphology. 1993; 26: 38–41. PMID: 8464224.

[22] Nagy L., Nagata M., Szabo S. Protein and non-protein sulfhydryls and disulfides in gastric mucosa and liver after gastrotoxic chemicals and sucralfate: Possible new targets of pharmacologic agents. World J. Gastroenterol. 2007; 13 (14): 2053–2060. DOI: 10.3748/wjg.v13.i14.2053.

[23] Ayala A., Muñoz M.F., Argüelles S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malon­dialdehyde and 4-hydroxy-2-nonenal. Oxidative Med. Cell. Longevity. 2014; 2014: 360438. DOI: 10.1155/2014/360438.

RIGHTS & PERMISSIONS

Kalinin R.E., Suchkov I.A., Maksaev D.A., Abalenikhina Y.V.